Early detection opportunity Veravas focuses on early-stage detection of Alzheimer’s disease and other neurological conditions using VeraBIND technology. This positions sales potential with neurology clinics, primary care networks, memory clinics, and research institutions seeking earlier, more accurate biomarkers.

Blood-based tau tests The VeraBIND Tau assay is a first-in-class blood test for pathological tau activity, enabling non-invasive screening. Target potential buyers include diagnostic laboratories, hospital systems, and commercial labs expanding their neurology panels.

Commercial availability With VeraBIND Tau launched for broad commercial availability, there is an opportunity to upsell into existing lab customers and distribute through clinical partners, emphasizing test adoption, reimbursement support, and volume-driven pricing.

Strategic partnerships Veravas has pursued external collaborations (e.g., with Phanes Biotech) on tau pathology testing, signaling opportunities for co-development, licensing, and joint go-to-market arrangements with biotech and contract research organizations.

Market expansion potential Evidence of independent analyses validating VeraBIND Tau’s accuracy at AAIC and ongoing communications around disease pathways indicate readiness for broader market education campaigns, targeting neurology networks, aging services, and dementia-focused care groups to drive adoption.